







an Open Access Journal by MDPI

Cancer Stem Cells and Drug Resistance

Collection Editor:

Message from the Collection Editor

Dr. Giovanni Amabile

Chief Executive Officer, Enthera, Milano, Italy

Dear Colleagues,

Cancer stem cells (CSCs) are a special subgroup of tumor cells and are suggested to be responsible for drug resistance and cancer relapse, mainly due to their ability to both self-renew and resist drug targeting. In the last few years, the scientific community has dedicated significant effort to generating new strategies to eradicate this population to sensitize the tumor to new therapies. Unfortunately, this cell population still represents the cause of several treatment failures. For this collection, entitled "Cancer Stem Cells and Drug Resistance", we welcome original research contributions that focus on advances and novel strategies to overcome drug resistance driven by cancer stem cells, as well as other challenges and new findings in the field of cancer stem cell research.

Dr. Giovanni Amabile Guest Editor













an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Alexander E. Kalyuzhny

Neuroscience, UMN Twin Cities, 6-145 Jackson Hall, 321 Church St SE, Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen, Copenhagen, Denmark

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. Cells encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Cell Biology*) / CiteScore - Q1 (*General Biochemistry, Genetics and Molecular Biology*)

Contact Us